Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Examine the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH)
with immune-responsive phenotype serum interleukin-6 (IL-6) ≥ 2.73 pg/mL who have an
inadequate response to existing drugs.
Phase:
Phase 2
Details
Lead Sponsor:
International University of Health and Welfare
Collaborators:
Japan Agency for Medical Research and Development Keio University